BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 16, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), unveiled new data
about the treatment of arterial calcification at the 2014 Transcatheter
Cardiovascular Therapeutics (TCT) conference in Washington D.C. Arterial
calcium is a common occurrence for the millions of patients suffering
from peripheral artery disease (PAD) and it can lead to significant
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus Canada NewsWire
Presented in 'State of the Art and Featured Research Session' at the
2014 European Society of Cardiology Congress
TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB , Sept.
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) will host a live
webcast of its fiscal 2015 first-quarter conference call on Wednesday,
October 29, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin,
President and Chief Executive Officer, and Larry Betterley, Chief
Financial Officer, will discuss the company’s results for its fiscal
first quarter ended September 30, 2014, and its financial outlook.
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today announced that
it has received CE (Conformité Européenne) Mark for its Stealth 360º
Orbital Atherectomy System (OAS). Stealth 360º is a percutaneous OAS
that is indicated to treat patients who suffer from peripheral arterial
“Securing CE Mark for Stealth 360º greatly expands our market
opportunity and is an important milestone toward benefiting patients in
Europe suffering from PAD—especially those with critical limb ischemia,
(CLI) who have been underserved by other treatment options,” said David
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device
company developing and commercializing innovative interventional
treatment systems for peripheral and coronary artery disease, today
reported financial results for its fiscal first quarter ended September
Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced charitable donations totaling more
than $1 million to be granted between 2014 and 2016 to seven nonprofit
organizations that support patients with cardiovascular disease.
- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) - On all-cause mortality, LCZ696 doubled the effect that enalapril, an ACE-inhibitor, previously showed vs.
Sign-up for Sunshine Heart to Provide Clinical Updates From the North American Feasibility Study and OPTIONS HF European Post-Market Study at 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference investment picks
Premium Membership: Features and Benefits
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.